Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Instead of waiting for physical tech transfer runs, biotech startups can use CFD to determine whether a process refined in micro-bioreactors will run safely in a CDMO's specific reactor fleet. Performing this virtual scale-up in advance derisks facility selection, reduces timeline and financial commitments, and provides verifiable technical proof for prospective investors.

Related Insights

Because CFD operates strictly on physical parameters rather than biological mechanisms, a vessel needs to be fully characterized only once across 100 to 200 operational points. When switching to a new molecule, media, or cell line, the scale-up software only needs updated fluid properties such as viscosity, density, surface tension, and salt concentration, eliminating the need to re-run simulations from scratch.

Early CFD adoption in biotech faltered because limited compute power forced engineers to use geometric simplifications, such as simulating a single periodic cake slice instead of the entire reactor cylinder. Bioreactors contain massive three-dimensional wrapping flows that cannot be captured in periodic wedge models. These simplifications produced inaccurate results, leading teams to experience poor outcomes and abandon simulation for years.

By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.

Conventional scale-up rules of thumb, such as constant power per volume, fail to accurately reproduce cellular microenvironments when working with shear-sensitive cell therapies or delicate organisms like Streptomyces. By simulating and matching comprehensive physical parameters across vessels using CFD, teams achieve far more comparable cell morphology and reliable cell growth without relying on protective additives like antifoam.

Massive CFD simulation datasets can be distilled into compact reduced-order surrogate models of just a few megabytes using machine learning. Rather than sifting through overwhelming data files, the model interpolates between simulated test points to predict key bioreactor parameters—including kLa, shear rate distribution, and mixing times—in milliseconds for any given operating condition.

Characterizing a bioreactor requires careful boundary setting because every additional variable exponentially increases the required simulation count. Adding wide continuum ranges for parameters like working volume or fluid viscosities creates an enormous operational space. Teams must strategically limit variables to discrete, sensible operating increments rather than attempting to model extreme spectrums from empty vessels to honey-like viscosities.

The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.

AI models mirror a bioreactor in real time, creating a "digital twin." This allows operators to test process changes and potential failure modes virtually, without touching the actual, expensive physical system, much like having a virtual engineer working alongside them.

Regulators welcome validated CFD data because it replaces unnecessary wet experiments and wasted process media. While the manufacturing-focused ASME V&V 80 standard is still being drafted, drug developers can already submit manufacturing CFD models to the FDA by applying the existing ASME V&V 40 medical device standard's credibility assessment framework.

When deviations or disturbances occur in continuous bioprocessing, determining the exact volume of impacted material downstream is difficult. Through first-principle CFD and rapid response models across stirred tanks, connectors, filters, and chromatography units, teams can simulate the whole residence time distribution chain to pinpoint precisely which product must be discarded and which can be retained safely.